Introduction
============

Retinitis pigmentosa (RP) is a highly heterogeneous form of inherited retinal degeneration that affects approximately 1.5 million individuals worldwide \[[@r1]\]. Individuals affected with RP initially experience night blindness, followed by progressive loss of visual fields, often culminating in legal or complete blindness. Clinical symptoms of RP include pigmentary bone spicules, optic disc pallor, attenuated blood vessels, and reduced or absent rod and cone electroretinograms (ERGs) \[[@r2]\].

RP is a highly heterogeneous disease that can be inherited in an autosomal dominant, autosomal recessive, X-linked, or digenic fashion and is associated with syndromic diseases such as Bardet-Biedl and Usher syndrome \[[@r3]\]. To date, 23 adRP, 39 arRP, and three XlRP associated genes have been identified, while the genes for several mapped loci are still unknown ([RetNet](https://sph.uth.edu/retnet)). Proteins from RP-associated genes are involved in a wide variety of cellular processes, including phototransduction, photoreceptor outer segment structure, splicing, transcriptional regulation, and intraflagellar transport, to name a few \[[@r4],[@r5]\].

Mutations in the *SNRNP200* gene located on chromosome 2q11.2 were initially identified in 2009 as a cause of the RP33 form of adRP \[[@r6]\]. *SNRNP200* encodes Brr2, a 200 kDa helicase involved in the catalytic activation of the RNA spliceosome \[[@r6]\]. Brr2 unwinds the U4/U6 duplex allowing the U4 complex to be released and U6 to bind to U2, and is involved in spliceosome disassembly. Brr2 is thought to be tightly regulated by Pfp8, another adRP-associated protein, and Snu114 GTPase \[[@r7]\]. A recent study suggests that the C-terminal of Prp8 is inserted into the RNA binding tunnel of Brr2 thus inhibiting Brr2 RNA binding and U4/U6 unwinding activity \[[@r8]\].

The hBrr2 protein is composed of two DExD/H box domains, two Sec63 domains, and a helicase superfamily C-terminal domain \[[@r9]\]. Studies have shown that both DExD/H domains bind Prp8 and that disease-associated mutations in Prp8 weaken binding to hBrr2 \[[@r10]\]. The majority of *SNRNP200* mutations found to date are located in the first DExD/H domain with the exception of the p.Ser1087Leu mutation. It is reasonable to speculate that the majority of mutations might affect Prp8 interactions, but how the p.Ser1087Leu mutation, located in the first Sec63 domain, causes disease remains to be determined \[[@r6],[@r10],[@r11]\].

The human *SNRNP200* gene is composed of 45 exons, which likely has contributed to the small number of reports describing mutation screening in a large number of families \[[@r11]\]. This project examined our well-characterized adRP cohort and additional families from the [eyeGENE](http://www.nei.nih.gov/eyegene)® Network for mutations in the *SNRNP200* gene \[[@r12]-[@r14]\]. Seven mutations were identified in our study cohort, two of which are novel, demonstrating that *SNRNP200* mutations cause an appreciable fraction of adRP.

Methods
=======

Samples
-------

The patient cohort used in this study has been described in detail previously \[[@r12],[@r15]-[@r17]\]. This cohort consists of 251 families with a high likelihood of autosomal dominant RP. Families without previously identified mutations were selected for *SNRNP200* testing. In addition, 21 families from the [eyeGENE](http://www.nei.nih.gov/eyegene)® consortium were tested as part of this study. Similar to the adRP cohort, the [eyeGENE](http://www.nei.nih.gov/eyegene)® consortium families have a provisional diagnosis of adRP, three affected generations, or two affected generations with male-to-male transmission and no previously identified mutation. DNA from a minimum of one affected individual from each family was tested for mutations.

This study was performed in accordance with the Declaration of Helsinki, and informed written consent was obtained from all participants. This research was approved by the Committee for the Protection of Human Subjects at the University of Texas Health Science Center Houston and by the respective human subjects' review boards at each participating institution including UC San Francisco and UC Berkeley. Subjects who underwent high-resolution retinal imaging at UC San Francisco and UC Berkeley received a stipend for time spent during the imaging sessions.

Sequencing analysis
-------------------

PCR primers to amplify each *SNRNP200* exon and intron/exon junctions were designed using Primer 3 \[[@r18]\]. Genomic DNA was amplified using selected primers tailed with M13 sequences ([Table 1](#t1){ref-type="table"}), Amplitaq Gold® 360 Master Mix (Life Technologies, Grand Island, NY), and standard thermocycling conditions with an annealing temperature of 56 °C.

###### *SNRNP200* primers.

  **Exon**    **Forward Primer Sequence (5′-3′)**        **Reverse Primer Sequence (5′-3′)**
  ----------- ------------------------------------------ -----------------------------------------------
  1           TGTAAAACGACGGCCAGTCCACATATCCCGCTCAGAAG     CAGGAAACAGCTATGACCCCTTCGTTTTCGTGGCTCT
  2           TGTAAAACGACGGCCAGTTTCCATCAGCTGGGGTAACT     CAGGAAACAGCTATGACCAGCAAAAATGCTGCTCGAAT
  3           TGTAAAACGACGGCCAGTCCATGAAGCTGAGGAGAGGA     CAGGAAACAGCTATGACCCTGCCAGCCATCAGTCAAC
  4           TGTAAAACGACGGCCAGTGGTGTGGCTCTTCACATCCT     CAGGAAACAGCTATGACCGGGAACTCACTGACATTAAGGTTT
  5           TGTAAAACGACGGCCAGTGAGAGGTAGTCGGGGAGGAC     CAGGAAACAGCTATGACCACTAGAGAGCTTGTTTACACTAGAAGG
  6           TGTAAAACGACGGCCAGTTTGAGGGAGAGGTTCTGTGG     CAGGAAACAGCTATGACCACCTAGGCATGGGGAAGAAG
  7 and 8     TGTAAAACGACGGCCAGTAACTTGGTTGCAGGGTGGT      CAGGAAACAGCTATGACCGGAGGAGGAAATAAGGCAAAA
  9           TGTAAAACGACGGCCAGTTCTTTCTACCCTGAGGATGGTT   CAGGAAACAGCTATGACCAGCTTCATGCTGCAATCTTC
  10 and 11   TGTAAAACGACGGCCAGTGGGGCAGAAAAGGACAAGA      CAGGAAACAGCTATGACCTTTTGGTCAATGGTTGAAATC
  12          TGTAAAACGACGGCCAGTATCCTGGCAATCCCACAATA     CAGGAAACAGCTATGACCGGTGGGGGTGGAAATAAAAA
  13          TGTAAAACGACGGCCAGTGGGAAATAAGCCCATGGAAG     CAGGAAACAGCTATGACCTCTTGGAAATGGGGAGAGAA
  14          TGTAAAACGACGGCCAGTCCAATGCCCTACACTCCAAT     CAGGAAACAGCTATGACCGCCTACAGAAAAGGCAGCAA
  15          TGTAAAACGACGGCCAGTGCTTGGGATCCCTTGTCTTT     CAGGAAACAGCTATGACCCCCAGTAGCACTCCTTGGAA
  16          TGTAAAACGACGGCCAGTATATTGCTCTTGGGGCAGTG     CAGGAAACAGCTATGACCGGTGAATCAAACATTCGAAAGAA
  17          TGTAAAACGACGGCCAGTTGATGGTGCAACTTCTGCTT     CAGGAAACAGCTATGACCCCTTAACCCATGGGAAACAA
  18          TGTAAAACGACGGCCAGTAGGGTCTCATGGGAGGAGAT     CAGGAAACAGCTATGACCTGGCACAAACTTGACATTGC
  19          TGTAAAACGACGGCCAGTCTGAGGCCAACTGCCTAGAG     CAGGAAACAGCTATGACCTCTGCTAGCTTTCCAGCATC
  20          TGTAAAACGACGGCCAGTGGATGCTGGAAAGCTAGCAG     CAGGAAACAGCTATGACCACAATAGGGACCGACCCACT
  21          TGTAAAACGACGGCCAGTATTCATGGGAGCCTGTCATT     CAGGAAACAGCTATGACCTCACATCAAGAGAGCAATCTGAA
  22 and 23   TGTAAAACGACGGCCAGTGGACAATAATGACATTGGGTCA   CAGGAAACAGCTATGACCGAGCAGGAAACCACACATGA
  24          TGTAAAACGACGGCCAGTCTGGCCTGGATGCTCAGA       CAGGAAACAGCTATGACCAGGATGCACACAGCACACAG
  25          TGTAAAACGACGGCCAGTCCGTGTGTAGAGTGGCTCAT     CAGGAAACAGCTATGACCTTTCCCATCAGACCCTTGG
  26          TGTAAAACGACGGCCAGTAAGCCATGAAGTGGGTGGT      CAGGAAACAGCTATGACCCACAGGCCTAGGAACAGGAA
  27          TGTAAAACGACGGCCAGTAGGGAAGACCCTACCCCTTT     CAGGAAACAGCTATGACCCCAACAGGAGCAAGGGTAAA
  28          TGTAAAACGACGGCCAGTGAAAAGGTGAGGCTTTGCTG     CAGGAAACAGCTATGACCCGGGACAAAGTGCAAGACAT
  29          TGTAAAACGACGGCCAGTCTTGCTGGGGACAGAGTGAT     CAGGAAACAGCTATGACCAGACCTCCCAAGTGCCTGAG
  30          TGTAAAACGACGGCCAGTTGATCCATGTCCCAGTCC       CAGGAAACAGCTATGACCAAAGCCTTCATACGGAATCA
  31          TGTAAAACGACGGCCAGTTTTGGCATCTCAGGTTTTCC     CAGGAAACAGCTATGACCCGTCCTCAGACCCAAACATT
  32          TGTAAAACGACGGCCAGTCTGTTCACAAAGGGGACCTC     CAGGAAACAGCTATGACCGACCGGGGAGAAGAAAAGAC
  33          TGTAAAACGACGGCCAGTCGTCTGTGGGGTGTCACATA     CAGGAAACAGCTATGACCATTCCTGGCAGACACTTTGC
  34          TGTAAAACGACGGCCAGTTGCACAGCTGGCAAAGTG       CAGGAAACAGCTATGACCCGCACCCCTCAAGTTTAACA
  35          TGTAAAACGACGGCCAGTCCATGAGGCAGTGAGCCTAC     CAGGAAACAGCTATGACCCCCTAACACCTTTTCTTCATCCT
  36          TGTAAAACGACGGCCAGTAGTTGGGCTTCCTGAGCAT      CAGGAAACAGCTATGACCTGTGTAAATAAGAGAGGCAGAAGTT
  37          TGTAAAACGACGGCCAGTAGGTCTCACACAGGGACCAT     CAGGAAACAGCTATGACCCTATGGAGGCGAGAGGTGAG
  38          TGTAAAACGACGGCCAGTACGTGATCCTTTGGTGGTTC     CAGGAAACAGCTATGACCCAGGCAGAGAAGGAGCAGAA
  39          TGTAAAACGACGGCCAGTATGACACTGCAGGGGACAG      CAGGAAACAGCTATGACCAGGGATGCCATGTGCTCT
  40          TGTAAAACGACGGCCAGTCTTTGGCCTGAGCTGGTC       CAGGAAACAGCTATGACCATAAAAGTGGGCGGAGTTGG
  41          TGTAAAACGACGGCCAGTGAGGGGTCAGTGGTGCTCTA     CAGGAAACAGCTATGACCCACCTTCGGAGGAACCATAA
  42          TGTAAAACGACGGCCAGTTCTTTGCTGCCTGTGTCATT     CAGGAAACAGCTATGACCTCAGTGATGGGGCAGTGG
  43          TGTAAAACGACGGCCAGTCCTGTTGGGCACAGCATAAT     CAGGAAACAGCTATGACCGCCCTTGTACCAAGCACCTA
  44          TGTAAAACGACGGCCAGTCTGTACCATTTTCATGGTTGC    CAGGAAACAGCTATGACCGCATGGACACAGGAAGCATT
  45          TGTAAAACGACGGCCAGTAGCATTTGTTCTGGCATGG      CAGGAAACAGCTATGACCGGACAGCACACCTAATGAGC

PCR products were treated with ExoSap-IT® (Affymetrix, Santa Clara, CA) and sequenced with M13 primers using BigDye® v1.1 (Life Technologies). Sequence reactions were treated with BigDye XTerminator® (Life Technologies) and run on a 3500XL Genetic Analyzer (Life Technologies). Sequence analyses were performed using SeqScape® v2.7 software and novel variants were assessed using polymorphism phenotyping ([PolyPhen-2](http://genetics.bwh.harvard.edu/pph2/)) and Sorting Intolerant From Tolerant ([SIFT](http://sift.jcvi.org/)).

Clinical evaluations
--------------------

Patients underwent standard ophthalmic evaluations including electroretinograms, and Goldmann visual field evaluation. High-resolution retinal images were obtained using spectral domain optical coherence tomography (SD-OCT) and adaptive optics scanning laser ophthalmoscopy (AOSLO) in each eye of subject UTAD701--01, and images were analyzed using custom-written software to determine cone spacing measures using previously described methods \[[@r19]-[@r21]\]. The cone spacing measures were compared with measures from 24 age-similar control subjects and z-scores, or standard deviations from the mean value of control subjects at a given retinal eccentricity, were calculated; z-scores greater than 2 were considered abnormal. For patient UTAD786--01 from the [eyeGENE](http://www.nei.nih.gov/eyegene)® repository, clinical information was extracted from the [eyeGENE](http://www.nei.nih.gov/eyegene)® database.

Results
=======

Individuals tested
------------------

Seventy-five of the families tested in this study were from our previously described adRP cohort. This cohort is a set of 251 families with a high likelihood of having autosomal dominant RP. At least one individual from most of these families had been tested previously for mutations in the entire coding region of *CA4, CRX, FSCN2, IMPDH1, NRL, PRPF31, RDS, RHO, ROM1, RP9, TOPORS, RPGR,* and *RP2*, and the mutation hot spots of *RP1, PRPF31, PRPF8, NR2E3*, and *KLHL7*. Mutations were identified in 176 of the families, who were excluded from this study.

Twenty-one families were also selected from the eyeGENE Network for this study. These families met criteria similar to those for the adRP cohort: i) a diagnosis of adRP, ii) a pedigree showing three affected generations or two affected generations with the presence of male-to-male transmission, and iii) negative findings from adRP testing performed earlier in our CLIA-certified DNA diagnostic laboratory.

Sequencing of genomic DNA or whole-genome amplified (WGA) DNA from 96 probands for mutations in *SNRNP200* was performed using the "gold standard" for mutation detection, traditional dideoxy sequencing. Potential disease-causing variants were identified in eight of the probands tested. Stock genomic DNAs from these eight probands and any additional available family members were tested independently for the presence of the identified *SNRNP200* variant. One variant, p.Gly1162Glu, was dropped from further consideration when its presence was not confirmed in the proband's genomic DNA. We believe this variant was introduced into the initially tested DNA sample during the whole-genome amplification process as the variant is present in all WGA DNA, but absent from genomic DNA stocks. The remaining seven *SNRNP200* variants were verified in genomic DNA and are believed to be pathogenic mutations ([Table 2](#t2){ref-type="table"}).

###### SNRNP200 mutations identified

  Family    exon with mutations   DNA change (NM_014014.4)   Protein Change   Previously Reported       SIFT Score   Polyphen Score
  --------- --------------------- -------------------------- ---------------- ------------------------- ------------ ----------------
  RFS048    13                    c.1625 C\>T                p.Ala542Val      Novel                     0            1.00
  UTAD565   16                    c\. 2041 C\>T              p\. Arg681Cys    Yes \[[@r11]\]                         
  UTAD728   16                    c\. 2041 C\>T              p.Arg681Cys      Yes \[[@r11]\]                         
  RFS910    16                    c\. 2044 C\>T              p.Pro682Ser      Novel                     0            0.99
  UTAD543   16                    c\. 2042G\>A               p\. Arg681His    Yes \[[@r11]\]                         
  UTAD701   25                    c.3260C\>T                 p.Ser1087Leu     Yes \[[@r27]\]                         
  UTAD786   25                    c.3260C\>T                 p.Ser1087Leu     Yes \[[20](_ENREF_20)\]                

*SNRNP200* mutations and phenotypes
-----------------------------------

A p.Arg681Cys heterozygous mutation was identified in probands from the UTAD565 and UTAD728 families ([Figure 1A](#f1){ref-type="fig"}). This mutation is caused by a C to T substitution at nucleotide 2041 and has been described previously in one family with adRP \[[@r11]\]. Sequencing of three additional affected members and one unaffected member of the UTAD565 family and two additional UTAD728 family members demonstrated that the p.Arg681Cys mutation segregates with disease, further substantiating the mutation's pathogenicity.

![Families with *SNRNP200* mutations. **A**: Two families with a c.2041C\>T, p.Arg681His mutation. **B**: Two families with a c.3260C\>T, p.Ser1087Leu mutation **C**: Family with a c.2042G\>A, p.Arg681His mutation **D**: Family with c.1625C\>T, p.Ala542Val mutation **E**: Family with a c.2044C\>T, p.Pro682Ser mutation. Circles indicate women; squares indicate men. Black filled symbols are affected individuals, grey filled symbols are possibly affected individuals, and open symbols are unaffected individuals. Arrows indicated each family's proband. Individual ID numbers corresponding to [Table 2](#t2){ref-type="table"} are underneath each symbol.](mv-v19-2407-f1){#f1}

Three members of UTAD565 and three members of UTAD728 were clinically examined ([Table 3](#t3){ref-type="table"}). The age of onset reported by these family members ranged from 4 to 35 years of age with severely reduced visual fields and non-detectable ERGs seen by the fourth decade of life. One member of the UTAD565 family, UTAD565--00, who, based on pedigree structure, must carry the p.Arg681Cys mutation, was examined at 66 years of age. Extensive clinical assessment of UTAD565--00 showed remarkably normal function of both eyes, including 20/20 visual acuity and full peripheral visual fields to all but a tiny test light (Goldmann Perimeter, I4e white target, slight horizontal constriction to 105° versus 125° normally). Her dark-adapted visual threshold sensitivity was normal centrally for both eyes, ERG responses reached fully normal amplitudes for both eyes (b-wave 440 microvolt dark-adapted and 84 microvolt light-adapted), and even the 30 Hz flicker response amplitude was normal (63 microvolt), although with delayed implicit time (35.2 msec versus normally \<32 msec).

###### Clinical Examination of select SNRNP200 patients.

  **Patient ID**   **Age of onset**   **Age of exam**   **Visual acuity**          **Visual field (degrees across horizontal meridian)**           **Dark-adapted combined / mixed response wave values**   **Light-adapted response - Flicker response wave values**
  ---------------- ------------------ ----------------- -------------------------- --------------------------------------------------------------- -------------------------------------------------------- -----------------------------------------------------------
  RFS048--5420     5                  14                20/32 OD 20/40 OS          18° OD^S^ 18° OS^S^                                             8.5                                                      2.3
  RFS048--4884     21                 40                20/40 OD 20/32 OS          9° OD^S^\* 12° OS^S^\*                                          non-detectable (at age 28)                               0.6 (at age 28)
  RFS048--4879     not known          46                20/40 OD 20/32 OS          not done                                                        14.6                                                     8.6
  RFS910--01       not known          50                20/40 OD 20/50 OS          6° OD^K^ \<5° OS^K^                                             non-detectable                                           non-detectable
  UTAD543--01      13                 76                10/200 OD HM @ 2 feet OS   5° OD^K^ 7° OS^K^                                               non-detectable                                           non-detectable
  UTAD565--02      8                  59                3/200 OD 20/400 OS         \<5° OD^K^ 8° OS^K^                                             non-detectable (at age 40)                               non-detectable (at age 40)
  UTAD565--01      24                 24                20/60 OD 20/50 OS          35° OD^K^ with temporal island 35° OS^K^ with temporal island   non-detectable                                           2.1
  UTAD565--00      NA                 66                20/20 OD 20/20 OS          145° OD^K^ 145° OS^K^                                           Within normal limits                                     Within normal limits
  UTAD701--01      4                  34                20/63 OD 20/50 OS          110° OD^K+^ 105° OS^K+^                                         severely reduced^t^                                      11.0
  UTAD728--01      12                 47                20/100 OD 20/160 OS        20° OD^S^ 20° OS^S^                                             not done                                                 not done
  UTAD728--02      20                 54                20/640 OD 20/160 OS        5° OD^S^ 10° OS^S^                                              not done                                                 not done
  UTAD728--03      35                 50                20/25 OD 20/20 OS          not done                                                        not done                                                 not done
  UTAD786--01      10                 30                20/25 OD 20/25 OS          100° OD^K^ 75° OS^K^                                            not done                                                 not done

Age of onset was based on patient self-reporting with the exception of UTAD565--02 which was based on medical records. ^K^=kinetic visual field by Goldmann perimeter: III4e unless otherwise noted; ^S^=static visual field by Humphrey perimeter: 30--2, spot size III unless otherwise noted; ^\*^Spot size was used ^V^\# I4e isopter ^+^V4e isopter ^t^B24Blink artifact from this patient contaminated mixed a and b wave measurements such that an exact value couldn\'t be determined.

Probands from the UTAD701 and UTAD786 families have a heterozygous p.Ser1087Leu mutation in *SNRNP200* ([Figure 1B](#f1){ref-type="fig"}). This mutation has also been described previously and is caused by a C to T substitution at nucleotide 3260. No additional family members were available for testing. Limited clinical data for UTAD786--01 suggest relatively early onset of symptoms, but slow progression of retinal degeneration ([Table 3](#t3){ref-type="table"}).

UTAD701--01 retained peripheral visual field sensitivity to V4e and III4e size targets, but fields were severely constricted to the central 10° to a I4e stimulus at age 34 ([Figure 2B](#f2){ref-type="fig"}). Visual acuity was reduced to 20/63 in the right eye and 20/50 in the left eye, and the scotopic and photopic ERG responses were severely reduced in each eye ([Table 2](#t2){ref-type="table"}). High-resolution retinal images using SD-OCT showed cystoid macular edema centrally; the inner segment ellipsoid zone band extended 5 degrees from the fovea nasally and temporally ([Figure 2C](#f2){ref-type="fig"}). AOSLO images of UTAD701--01 showed preserved cone mosaics centrally within cystoid spaces ([Figure 2D-E](#f2){ref-type="fig"}). Where cone mosaics were observed permitting quantitative analysis, cone spacing was increased by 3.5--7.9 standard deviations above the normal mean ([Figure 2E](#f2){ref-type="fig"}).

![Clinical features in UTAD701--01, right eye. **A**: Color fundus photograph shows retinal vascular attenuation and mild disc pallor; thin white lines outline the retinal region imaged using adaptive optics scanning laser ophthalmoscopy (AOSLO); the thick horizontal white line indicates the spectral domain optical coherence tomography (SD-OCT) location. **B**: Goldmann visual field testing shows constriction to the I4e target (blue lines). **C**: Horizontal SD-OCT through the anatomic fovea shows cystoid macular edema near the fovea; the inner segment ellipsoid zone band extends about 5 degrees from the fovea with loss of outer retinal layers at greater eccentricities. **D**: High-resolution foveal images acquired using adaptive optics scanning laser ophthalmoscopy (AOSLO) reveal walls of cystoid spaces (dark lines). Cones are visible within the cystoid spaces. **E**: Cone spacing increased by 3.5--7.9 standard deviations above the normal mean (white numbers: standard deviations from normal mean, small white spots and the red circle indicate fixation locus). Scale bars=1°.](mv-v19-2407-f2){#f2}

The other previously reported mutation detected in our testing was a p.Arg681His missense mutation in the UTAD543 family \[[@r11]\]. The individual examined in this family indicated an onset of symptoms at age 13, and when seen at age 76, had non-detectable ERGs, very restricted visual fields, and slightly more than hand motion acuity ([Table 3](#t3){ref-type="table"}).

Two novel *SNRNP200* mutations were also detected in this study and not observed in any unaffected family members, controls, or databases. A p.Ala542Val *SNRNPR200* mutation caused by a C to T substitution at nucleotide 1625 was seen in three affected members of the RFS048 family and was absent in one examined, unaffected at-risk individual ([Figure 1D](#f1){ref-type="fig"} and [Table 2](#t2){ref-type="table"}). Segregation analysis of this variant along with "probably damaging" PolyPhen and "damaging" SIFT scores strongly suggest that this is the cause of RP in this family.

Clinical examination of the three affected RFS048 family members showed a variable age of onset and progression of symptoms ([Figure 3B-C](#f3){ref-type="fig"} and [Table 3](#t3){ref-type="table"}). The proband, RFS048--4884, reported onset at 21 years of age progressing to severely reduced photopic flicker responses (\<1 µV) and non-detectable scotopic mixed ERG responses by age 28; visual fields were constricted to \<15 degrees along the horizontal meridian by age 40. RFS048--5420, the proband's daughter, reported onset of disease symptoms at age 5 years. Her examination at age 14 showed severely reduced ERG responses (non-detectable dark-adapted rod, 2.3 µV 31 Hz flicker, and 8.5 µV mixed responses), in addition dark-adapted thresholds were elevated 2.4 log units, and visual fields were constricted to \<20 horizontal degrees. In contrast, at age 46, the proband's maternal aunt, RFS048--4879, was more moderately affected, retaining modest albeit significantly reduced ERG function (2.3 µV dark-adapted rod, 8.6 µV 31 Hz flicker, and 14.6 µV mixed responses).

![Fundus photographs from individuals with small nuclear riboprotein 200 kDa mutations. **A**: UTAD565-02 at age 59 with moderatively advanced retinitis pigmentosa . Her right eye fundus shows diffuse atrophy of the optic nerve and the retina outside the macula with heavy pigmentary deposits in the equator and vascular attenuation, while the macula area shows intact retinal pigment epithelium with no foveal reflex. **B**: RFS048--4884 at age 40 showed severe vascular attenuation and disc pallor. Extensive pigmentary disturbances were seen throughout the peripheral retina. **C**: RFS048-5420 at age 14 showed moderate vascular attenuation and disc pallor. Moderate pigment clumping was seen in the periphery. **D**: UTAD701-01 at age 34 shows vascular attenuation, mild disc pallor, and heterogeneous, mottled fundus pigment along the temporal arcades with preserved pigmentation in the central macula.](mv-v19-2407-f3){#f3}

The second novel *SNRNP200* variant observed in this study was a p.Pro682Ser in the RFS910 proband ([Figure 1E](#f1){ref-type="fig"}). This variant has not been seen previously, but mutations in the two adjacent codons, p.Arg681Cys and p.Val683Leu, have been reported previously and, in the case of p.Arg681Cys, also seen in this study \[[@r11]\]. PolyPhen and SIFT scores for the p.Pro682Ser mutation further increase the likelihood that this is a pathogenic mutation ([Table 2](#t2){ref-type="table"}).

Clinical examination of the RFS910 proband at age 50 showed visual acuity was reduced to 20/40 in the right eye and 20/50 in the left eye, scotopic and photopic ERGs were non-detectible, and dark-adapted visual thresholds were elevated greater than 4 log units ([Table 3](#t3){ref-type="table"}). A follow-up examination at age 56 indicated a further reduction in visual acuity to 20/80 and 20/250, Goldman visual field perimetry depicted a central field constricted to \<5 degrees in the right eye and was not measurable in the left eye.

Conclusions
-----------

Our analyses identified five *SNRNP200* mutations in seven families with adRP. One of these mutations, p.Arg681His, has been reported previously in only one patient \[[@r11]\]. Identifying an additional adRP family with this mutation strengthens its likelihood of pathogenicity. We also identified two novel *SNRNP200* mutations. The p.Pro682Ser mutation is adjacent to previously reported mutations, but the p.Ala542Val mutation that segregates in RFS048 is in a novel exon of the gene not previously associated with pathogenic mutations. These findings establish a *SNRNP200* mutation prevalence of 1.6% in our adRP cohort, while the presence of three additional mutations in the small number (n=21) of eyeGENE consortium samples potentially suggests an even higher *SNRNP200* mutation frequency.

With the exception of the p.Ser1087Leu mutation, the four remaining mutations identified in this study are located in the first DExD/H box domain. This domain has been shown to interact with Prp8 \[[@r9],[@r22]\]. It is likely that alteration of this binding interaction affects splicesome assembly or function and ultimately causes photoreceptor death.

The individuals and families with *SNRNP200* mutations had typical RP symptoms, including reduced or absent ERGs and decreased acuity and visual fields that ranged from mild to severe. Disease onset was reported to occur between 4 and 35 years of age with some individuals having non-detectable ERGs by age 24 and 28 ([Table 3](#t3){ref-type="table"}). Visual acuity was reduced in a patient with the p.Ser1087Leu mutation who retained peripheral visual field sensitivity to a large target, visual acuity was reduced. The patient had cystoid macular edema and although cones were visible near the fovea, cone spacing was significantly increased, consistent with foveal cone loss. Despite slow progression over 40 years and a preserved peripheral visual field, the fovea showed macular edema and cone loss, although SD-OCT images showed preservation of the inner segment ellipsoid zone band throughout this region.

Three of the seven pedigrees, RFS048, RFS910, and UTAD565, showed evidence of non-penetrance ([Figure 1](#f1){ref-type="fig"}). Although DNA from these non-penetrant individuals was not available for genetic screening, one of the non-penetrant individuals in UTAD565 was examined at age 66. This family member, UTAD565--00 ([Figure 1](#f1){ref-type="fig"}), was diagnosed as having normal vision, although a very small reduction in Goldman visual fields and a slightly delayed implicit time were detected clinically. These findings suggest that mutations in *SNRP200*, like those of other splicing factor genes such as *PRPF31*, can be non-penetrant, although often with sub-clinical findings, and raises the possibility that compensatory mechanisms may modify clinical expression of the gene as has been postulated for *PRPF31* \[[@r23]-[@r26]\].
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